建立和验证基于基因突变的风险模型,用于预测急性髓性白血病的预后和治疗反应
Yun Liu1, Teng Li2, Hongling Zhang1
1Department of Hematology, The People's Hospital of Weifang, Weifang, Shandong, 261041, China.
Heliyon
|June 4, 2024
概括
这项研究开发了一种基于基因突变的风险模型,用于预测急性髓性白血病 (AML) 患者的预后. 该模型准确地将患者分为高风险和低风险组,帮助治疗决策.
科学领域:
- 血液学 血液学 血液学
- 基因组学就是基因组学.
- 在瘤学瘤学.
背景情况:
- 急性髓性白血病 (AML) 是一种复杂的血液性恶性瘤.
- 目前针对AML的风险分层和向疗法受限于对其基因组景观的不完全理解.
- 需要改进的预后模型,包括基因突变数据.
研究的目的:
- 建立基于基因突变的AML患者预测性预后风险模型.
- 确定与AML预后相关的关键基因特征.
- 评估模型的预测性能和临床适用性.
主要方法:
- 下一代测序 (NGS) 用于识别118名AML患者的基因突变.
- 基于mRNA表达的分子亚型进行了共识聚类.
- 分析了差异表达基因 (DEGs),以使用单变和LASSO回归构建预后风险模型.
- 患者被分为高风险 (HR) 和低风险 (LR) 的两类.
主要成果:
- NGS确定了24个突变基因,其中CBL和SETBP1.1的高频率.
- 确定了两个具有独特免疫微环境和生存概率的分子亚型.
- 一个7基因签名 (MPO,HGF,SH2B3,SETBP1,HLA-DRB1,LGALS1,KDM5B) 形成了风险模型,显示LR患者的生存率更好.
- 诺米图表显示出强大的预测准确性 (AUC为1,3,5年生存率:0.829,0.81,0.811).
- HR病例对特定的向疗法的敏感性增加.
结论:
- 开发的基于基因突变的风险模型有效预测AML的预后.
- 该模型和名图为AML患者分层和指导治疗决策提供了有价值的工具.
- 这些发现增强了对AML基因组学及其对患者结果的影响的理解.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:20Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K